A Calcium Pill Just Beat Standard Care 76% to 4% — and Switched a Missing Hormone Back On in 91%

Q: When could encaleret be approved?

The FDA accepted the NDA with Priority Review and set a target action date of May 8, 2027; a marketing application is also under review at the EMA in Europe.

Picture your body’s calcium thermostat jammed on “way too high.” Your blood calcium is actually low, but a broken sensor keeps screaming the opposite, so your system shuts off the hormone that would fix it and flushes the calcium you can’t spare straight into your urine. That’s autosomal dominant hypocalcemia type 1 — ADH1 — and until now the only answer was to pour in more calcium and watch your kidneys take the hit.

Here’s the number that reframes the whole disease: 76% of patients on BridgeBio’s experimental pill encaleret hit both their blood-calcium and urine-calcium targets at 24 weeks. On conventional therapy, 4% did (GlobeNewswire). That’s 34 of 45 versus 2 of 45, same patients, with a p-value under 0.0001.

Today in Boston, at the ASBMR 2026 annual meeting, BridgeBio added the data that explains why (GlobeNewswire). The drug didn’t just move lab values — it restored the body’s own parathyroid hormone and, by the patients’ own accounts, made them feel human again.

The thesis: encaleret is one FDA decision away from becoming the first treatment that fixes what’s actually broken in ADH1 instead of mopping up after it.

🧠 Why This Matters

ADH1 comes from a gain-of-function glitch in the CASR gene, which builds your calcium-sensing receptor. Crank that receptor’s sensitivity too high and it behaves as if calcium is always abundant. So your parathyroid glands stop making parathyroid hormone (PTH), your blood calcium drops, and your kidneys dump calcium you desperately need.

The standard fix — megadoses of calcium and active vitamin D — raises blood levels but makes the kidney problem worse, loading the urine with calcium and inviting stones and long-term renal damage. You treat the reading on the dial while the machine keeps grinding.

Encaleret is a daily oral “calcilytic”: it turns the oversensitive receptor’s gain back down, so the glands switch PTH back on and the body manages its own calcium. Chronic hypoparathyroidism, the broader family this sits in, affects an estimated 200,000-plus people across the U.S. and EU.

“These findings suggest that encaleret is addressing the underlying biology of the disease.” — Erik Imel, M.D., Indiana University School of Medicine, who presented the bone data

📊 Deep Dive

The pivotal CALIBRATE trial enrolled 70 adults and randomized 67 of them 2:1 to encaleret or standard care. Small, because ADH1 is rare — but the gap between arms is hard to wave away. Encaleret versus conventional therapy at 24 weeks:

Blood + urine calcium both in target range: 76% vs 4%
PTH restored to at least the lower limit of normal: 91% vs 0%
Reported improvement in at least one ADH1 symptom: 100% vs 46%
Fatigue improved: 61.3% vs 27.3%
Muscle spasms improved: 58.1% vs 18.2%
Tingling improved: 51.6% vs 9.1%
Brain fog improved: 48.4% vs 9.1%

That 91%-versus-0% on PTH is the tell. Standard care never touches the hormone; it can’t. Encaleret brought it back in nearly everyone (StockTitan). Markers of bone formation and resorption rose too, which fits a body that’s finally cycling calcium the way it’s supposed to.

“We are extremely encouraged by the robust and positive findings of this registrational study.” — Scott H. Adler, M.D., Chief Medical Officer of Calcilytix, a BridgeBio affiliate

⚠️ The Catch

Encaleret is still investigational. Nobody can fill this prescription yet, and the FDA’s target decision date is May 8, 2027 (GlobeNewswire).

The trial is also small — 67 randomized patients — and the symptom and daily-functioning numbers are patient-reported, measured against an open comparison rather than a placebo. Impressive, but softer evidence than the lab endpoints. The rise in bone-turnover markers came without published figures, and faster bone turnover is something you want watched over years, not quarters.

And ADH1 itself is a narrow door. The large prize — the roughly 200,000 people with chronic hypoparathyroidism of other causes — sits behind a separate Phase 3, RECLAIM-HP, which only just dosed its first patient.

🎯 What Happens Next

The regulatory machine is already moving. The FDA accepted BridgeBio’s encaleret application in ADH1 with Priority Review and set that May 8, 2027 action date; a parallel filing is in with the EMA in Europe.

RECLAIM-HP is the one to watch after that: a global, double-blind, placebo-controlled study of about 160 adults and adolescents, randomized 3:1, with a 24-week primary endpoint on getting both blood and urine calcium into range. Clear that, and encaleret stops being a rare-disease footnote and becomes a franchise.

🧩 Bigger Picture

This is precision medicine doing exactly what it promises: find the specific protein a mutation broke — here, an overclocked calcium sensor — and tune it, rather than flooding the system with the end product and hoping. It’s the same logic behind the gene-targeted wave reshaping rare disease.

For BridgeBio, it’s also a second act. A company known for its approved heart drug is trying to prove it can run the play again, turning one launch into a pipeline of them. The economics of rare disease make that viable: small trials, orphan status in the U.S., EU and Japan, priority review, and pricing power per patient that a common-disease drug never gets.

The patients, meanwhile, just want the thermostat fixed. For the first time, a pill in late-stage testing looks like it can reach in and turn the dial back where it belongs — and let the body do the rest.

Sources

❓ Quick answers

What is encaleret and what disease does it treat?

Encaleret is BridgeBio's investigational oral drug for autosomal dominant hypocalcemia type 1 (ADH1), a rare genetic disorder of calcium regulation; Phase 3 CALIBRATE data were reported Oct 29, 2025 and expanded at ASBMR on Oct 11, 2026 (GlobeNewswire).

How well did encaleret work versus standard care?

In the Phase 3 CALIBRATE trial, 76% of encaleret patients hit both blood and urine calcium targets at 24 weeks versus 4% on conventional therapy (p<0.0001), and PTH was restored to normal range in 91% versus 0% (GlobeNewswire, Oct 11, 2026).

When could encaleret be approved?